Form 4: Acadia Officer Kihara Reports RSU Vesting, Tax Sales

Acadia Pharmaceuticals' Principal Accounting Officer, James Kihara, reported the vesting of restricted stock units and subsequent mandatory sales to cover tax obligations.

Summary

• James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals Inc., reported multiple transactions involving the company's common stock.
• On March 24, 2026, Kihara acquired 1,627 shares of common stock through the vesting of restricted stock units.
• On March 25, 2026, Kihara acquired 2,142 shares of common stock through the vesting of restricted stock units.
• To cover withholding taxes and tax-related items associated with these RSU vestings, Kihara sold a total of 1,942 shares (833 shares at $21.47, 1,097 shares at $21.65, and 12 shares at $21.7253) on March 25 and March 26, 2026.
• These sales were mandatory and intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Exchange Act.
• Following these transactions, Kihara beneficially owns 26,885 shares of common stock directly.
• Kihara also holds 4,883 restricted stock units that began vesting on March 24, 2026, in four equal annual installments.
• Additionally, Kihara holds 4,284 restricted stock units that began vesting on March 25, 2025, in four equal annual installments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The vesting of RSUs is a positive for the officer, but the subsequent sales are routine tax-related transactions and do not signal a change in company fundamentals or management confidence.

Positives

• Vesting of 1,627 restricted stock units on March 24, 2026, and 2,142 restricted stock units on March 25, 2026, indicates continued equity compensation for a key officer.
• The transactions were executed under a Rule 10b5-1 plan, suggesting pre-planned and automated sales for tax purposes rather than discretionary selling.

Negatives

• Sales of 1,942 shares of common stock, totaling approximately $41,900, reduce the officer's direct ownership in the company.

Future Outlook

The filing indicates future vesting of restricted stock units for James Kihara, with installments beginning March 24, 2026, and March 25, 2025, suggesting ongoing equity incentives.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common across the biotechnology and pharmaceutical sectors. These transactions typically reflect standard compensation practices rather than a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation-related transactions by an officer, not indicative of a shift in company strategy or performance.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Future vesting of remaining restricted stock units in four equal annual installments, with one series beginning March 24, 2026, and another beginning March 25, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of restricted stock units and subsequent mandatory tax-related sales. Such transactions are common for executives and are typically pre-scheduled under Rule 10b5-1 plans, meaning they do not reflect discretionary trading based on new material information. Therefore, this filing alone does not provide a basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Acadia Pharmaceuticals, ACAD, James Kihara, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sales, Officer Transactions, Equity Compensation, Rule 10b5-1